Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Aptevo Therapeutics Inc. (APVO)
|
Add to portfolio |
|
|
|
| Price: |
$24.99
| | Metrics |
| OS: |
11.5
|
M
| |
-70
|
% ROE
|
| Market cap: |
$288
|
M
| |
|
|
|
Net cash:
|
$21
|
M
| |
$1.82
|
per share
|
|
EV:
|
$267
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
($1.67)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 12.3 | 4.3 | 0.0 | 23.1 | 14.7 | 10.0 | 33.6 |
| Revenue growth | 185.3% | | -100.0% | 57.4% | 46.8% | -70.3% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 11.2 | 5.0 | 12.5 | 16.9 |
| Gross profit | 12.3 | 4.3 | 0.0 | 11.9 | 9.6 | -2.5 | 16.7 |
| Gross margin | 100.0% | 100.0% | | 51.4% | 65.8% | -24.9% | 49.6% |
| Selling, general and administrative | | | | 28.1 | 34.6 | 36.2 | 43.0 |
| Research and development | 19.0 | 17.9 | 24.8 | 35.4 | 29.0 | 29.1 | 34.7 |
| General and administrative | 14.7 | 14.0 | 16.2 | | | | |
| EBITA | -21.4 | -27.5 | -41.0 | -51.7 | -53.1 | -67.0 | -57.7 |
| EBITA margin | -174.1% | -638.1% | | -224.0% | -362.6% | -670.6% | -171.7% |
| Amortization of intangibles | | | | | 0.8 | 0.8 | 3.4 |
| EBIT | -21.4 | -27.5 | -41.0 | -51.7 | -53.9 | -67.8 | -61.1 |
| EBIT margin | -174.1% | -638.1% | | -224.0% | -368.1% | -678.6% | -181.8% |
| Pre-tax income | -29.4 | -30.9 | -43.1 | -53.7 | -55.9 | -139.6 | -61.3 |
| Income taxes | -1.0 | -13.2 | -2.6 | 0.0 | -23.3 | -19.7 | -2.0 |
| Tax rate | 3.2% | 42.6% | 6.1% | 0.0% | 41.7% | 14.1% | 3.3% |
| Earnings from continuing ops | -30.4 | -44.1 | -45.7 | -53.7 | -72.2 | -127.4 | -59.3 |
| Earnings from discontinued ops | 1.0 | 13.2 | 2.6 | | 39.6 | 7.5 | |
| Net income | -29.4 | -30.9 | -43.1 | -53.7 | -32.6 | -119.9 | -59.3 |
| Net margin | -239.2% | -717.6% | | -232.8% | -222.3% | -1200.7% | -176.5% |
| |
| Diluted EPS | ($6.48) | ($13.00) | ($15.66) | ($2.39) | ($3.38) | ($6.29) | ($2.93) |
| Shares outstanding (diluted) | 4.7 | 3.4 | 2.9 | 22.5 | 21.3 | 20.2 | 20.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|